Abstract Background: COVID-19–related acute illness is associated with an increased risk of
venous thromboembolism (VTE). Objective: These evidence-based guidelines from the …

COVID-19 is associated with endothelial activation in the setting of a potent inflammatory
reaction and a hypercoagulable state. The end result of this thromboinflammatory state is an …

Introduction Venous thromboembolism (VTE) is a leading cause of cardiovascular morbidity
and mortality. The majority of VTE events are hospital‐associated. In 2008, the …

Despite the emergence of high quality randomized trial data with the use of antithrombotic
agents to reduce the risk of thromboembolism, end‐organ failure, and possibly mortality in …

Background Thromboprophylaxis for medically ill patients during hospitalization and
postdischarge remains underutilized. Clinical decision support (CDS) may address this …

Background Coronavirus disease of 2019 (COVID-19) is associated with venous
thromboembolism (VTE), not only during hospitalization but also after discharge, raising …

Ambulatory patients with coronavirus disease 2019 (COVID-19) have a low risk of
developing venous thromboembolism (VTE), whereas hospitalization is associated with a …

Background Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some
patients experience cardiovascular complications, including thromboembolic events and …

Septic patients were commonly affected by coagulation disorders; thus, they are at high risk
of thrombotic complications. In the last decades, novel knowledge has emerged about the …

Introduction Hospitalized COVID-19 patients, particularly those with high-risk features, are at
risk for venous and arterial thromboembolic events for approximately 30 days or more after …